Suraksha Diagnostic Share Price

Healthcare Services company Suraksha Diagnostic announced Q3FY26 results Revenue: Rs 783.09 million against Rs 601.12 million during Q3FY25, change 30%. EBITDA: Rs 237.82 million against Rs 188.55 million during Q3FY25, change 26%. EBITDA Margin: 30.6% for Q3FY26. PAT: Rs 72.41 million against Rs 59.85 million during Q3FY25, change 21%. PAT Margin: 9.3% for Q3FY26. Ritu Mittal, Joint Managing Director & CEO said: “We continued to generate strong quarterly top-line growth in Q3FY26 on the back of our robust networkexpansion. The EBITDA margin impact was attributable to the launch and development of new centres. Our centres whichare > 2 years old continue to operate at a strong 37% EBITDA, indicating the strength of our business model. Weare ‘Investing for Scale: Short-term Compression for Long -term Dominance’. In 9MFY26, we added 12 centres which are fully operational, while 6 are under development. With the launchof Suraksha Sutra, our Genomics/Molecular vertical, we have successfully forayed into the high-value genomicssegment, securing a strong first-mover advantage in Eastern India. We are committed to generating value for our shareholders and should be able to drive innovation, operationalexcellence and sustainable growth.” Result PDF

• Trendlyne
• 3 months 2 weeks ago

The company remains committed to its market in West Bengal while adding new centers in Odisha, Jharkhand, and Tripura, alongside strengthening its presence in Assam.

• NDTV Profit
• 5 months ago

Healthcare Services company Suraksha Diagnostic announced Q2FY26 results Total Income: Rs 795.80 million against Rs 680.67 million during Q2FY25, change 16.9%. EBTIDA: Rs 249.66 million against Rs 245.07 million during Q2FY25, change 1.9%. EBTIDA Margin: 31.7% for Q2FY26. PAT: Rs 88.28 million against Rs 101.56 million during Q2FY25, change -13.1%. PAT Margin: 11.2% for Q2FY26. Ritu Mittal, Joint Managing Director & CEO, said: “Suraksha reported another quarter of strong top-line growth, driven primarily by test volumes. The QoQ andYoY total revenue growth was 8.3% and 16.9%, respectively. I am happy to announce that we have added 11 centres in H1FY26. We are working on 3 hub centres and 6spoke centres, which will be operational in the second half of FY26, which will take the total count to 20 for theyear. In Q1FY26, we launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and moleculartesting services. The lab is now fully operational and we expect to leverage the same to drive future growth. As the new centres mature, their margin contributions will increase, moving overall performance closer toindustry benchmarks and supporting improved profitability across our network. We remain committed to creating value for our shareholders, driven by innovation, operational excellence andsustainable growth.” Result PDF

• Trendlyne
• 6 months 1 week ago